JG
MRSN

Jefferies Group’s Mersana Therapeutics MRSN Stock Holding History

Jefferies Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-904
Closed -$529 – 1478
2020
Q2 		$529 Buy
+904
New +$309K 0.01% 904

Other funds holding MRSN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jefferies Group's MRSN Position: Q4 2019 in Review

Jefferies Group sold out of Mersana Therapeutics (MRSN) in Q4 2019, closing a stake of 1,021 shares — an estimated $40K sold.

Jefferies Group first reported a position in MRSN in Q4 2018 and held it in 3 quarters. The position peaked at $1.37M in Q4 2018. 69 funds tracked by Wall St. Rank hold MRSN as of Q4 2019.

  • Jefferies Group reported no remaining Mersana Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 1,021 Mersana Therapeutics shares in Q4 2019, an estimated $40K.
  • Jefferies Group first reported a position in Mersana Therapeutics in Q4 2018 and held it in 3 quarters.
  • Jefferies Group's Mersana Therapeutics position peaked at $1.37M in Q4 2018.
  • 69 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.